Aromatic Amino Acid Decarboxylation Inhibitor class drugs

6 results
  • carbidopa

    (Carbidopa)
    Edenbridge Pharmaceuticals LLC.
    Carbidopa tablets are indicated for use with carbidopa-levodopa or levodopa to treat symptoms of idiopathic Parkinson's disease, postencephalitic parkinsonism, and symptomatic parkinsonism due to nervous system injury. They help reduce nausea, allow for lower levodopa doses, and facilitate dosage titration.
  • carbidopa and levodopa

    (Carbidopa and levodopa)
    Advagen Pharma Ltd
    Carbidopa and levodopa extended-release tablets are indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism resulting from carbon monoxide or manganese intoxication.
  • carbidopa and levodopa

    (carbidopa and levodopa)
    Rising Pharma Holdings, Inc.
    Carbidopa and levodopa orally disintegrating tablets are indicated for treating Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism following carbon monoxide or manganese intoxication. Carbidopa enhances levodopa’s effectiveness by reducing peripheral decarboxylation and may also lessen nausea, allowing for quicker dosage adjustments.
  • carbidopa-levodopa

    (carbidopa and levodopa)
    Advagen Pharma Ltd.,
    Carbidopa and levodopa tablets are indicated for treating Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism following carbon monoxide or manganese intoxication. Carbidopa enhances levodopa's effectiveness, allowing lower doses, reducing nausea, and facilitating faster titration.
  • dhivy

    (Carbidopa Levodopa)
    Avion Pharmaceuticals, LLC
    DHIVY is indicated for treating Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism resulting from carbon monoxide or manganese intoxication.